Can a tiny amount of dye protect kidneys during heart scans?

NCT ID NCT05906758

Recruiting now Disease control Sponsor: Tulane University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using very little contrast dye (less than 20cc) during coronary angiography is safer for patients who already have acute kidney injury. Researchers will compare immediate angiography with delayed angiography to see if ultra-low contrast reduces the risk of further kidney damage. The trial involves 32 hospitalized adults who need this heart procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ultra-low contrast coronary angiography (procedure using less than 20cc of contrast material)
What this could lead to: If successful, this could show that using very little contrast dye during heart imaging is safer for patients with kidney injury, potentially reducing the need for dialysis.
What could go wrong: This is a small early-phase trial with only 32 participants, so results may not apply to everyone. The ultra-low contrast approach might not provide clear enough images for diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY

Contacts and locations

Locations

Tulane University Medical Center
RECRUITING

New Orleans, Louisiana, 70112, United States
University Medical Center
RECRUITING

New Orleans, Louisiana, 70112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.